Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ARG2 | P78540 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686256 | 1.00 | LMNA (0.37) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL14481581 | 1.00 | LMNA (0.37) | LMNAMEN1KMT2AARG2GPR84 | |
| Water SCHEMBL25291409 | 0.97 | LMNA (0.35) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL414798 | 0.94 | LMNA (0.41) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL5053890 | 0.90 | ARG2 (0.40) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL1201076 | 0.90 | ARG2 (0.40) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL9903775 | 0.88 | MEN1 (0.47) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL21405561 | 0.88 | GPR84 (0.39) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL7586822 | 0.88 | GPR84 (0.39) | LMNAMEN1KMT2AARG2GPR84 | |
| SCHEMBL7585089 | 0.88 | GPR84 (0.39) | LMNAMEN1KMT2AARG2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-7862807-B2 | Dendrimers as molecular translocators | UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1545462-A4 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | UNIV CALIFORNIA (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060216265-A1 | Dendrimers as molecular translocators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-28 | — | — | US | disclosed |
| EP-1545462-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | The Regents of the University of California (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009665-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009666-A2 | DENDRIMERS AS MOLECULAR TRANSLOCATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216265-A1 | Dendrimers as molecular translocators | SLC29A1, SLC29A2, TSPO | LMNA 2444/4885MEN1 3202/4885KMT2A 4383/4885 |
| US-20080221020-A1 | Dendrimers as Molecular Translocators | SLC29A1, SLC29A2, TSPO | LMNA 2444/4885MEN1 3202/4885KMT2A 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.